ArticleBMJ neurology open2026
Efficacy of nebulised dexmedetomidine versus aminophylline for treatment of postdural puncture headache in patients undergoing subarachnoid block posted for caesarean section: a double-blind, randomised controlled study.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postdural puncture headache (PDPH) following spinal anaesthesia significantly affects postpartum recovery. We evaluated the efficacy of nebulised dexmedetomidine and aminophylline in women with moderate to severe PDPH after caesarean delivery. Methods: In this single-centre, double-blind, randomised controlled trial, 96 postpartum women, with American Society of Anesthesiologists physical status II, Visual Analogue Scale (VAS), with PDPH (VAS>4; Lybecker>2) after subarachnoid block were allocated to receive nebulised dexmedetomidine (1 µg/kg), aminophylline (1.5 mg/kg) or saline placebo. All participants received standardised conservative treatment and remained supine for 72 hours. Nebulisation was administered two times per day for ≤72 hours. The primary endpoint was change in VAS pain score at 24 hours. Secondary endpoints included VAS and Lybecker scores at 48 hours and 72 hours, Patient Global Impression of Change (PGIC) and adverse events. Results: Baseline characteristics were comparable between groups. At 24 hours, median VAS was significantly lower with dexmedetomidine (3 (3-4)) and aminophylline (4 (3-6)) compared with control (6 (5.5-6)) (p<0.001). Pain reduction persisted at 48 hours and 72 hours, with dexmedetomidine producing the fastest resolution. Lybecker scores improved earlier in the treatment groups (p<0.001). PGIC showed 'very much improved' in 100% (dexmedetomidine), 53.1% (aminophylline) and 0% (control) (p<0.001). Adverse events were mild and infrequent, with cough and nausea occurring only in the aminophylline group. Conclusions: Nebulised dexmedetomidine and aminophylline provided effective, well-tolerated, non-invasive treatment for PDPH. Dexmedetomidine produced the greatest and earliest improvement. These therapies may represent practical alternatives for PDPH management in postpartum patients; larger multicentre trials allowing early mobilisation are warranted. Trial registration number: Clinical Trials Registry-India (CTRI/2024/01/061322; date of prospective trial registration: 10 January 2024, date of first patient enrolment: 15 January 2024, https://ctri.nic.in/Clinicaltrials/login.php).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.